The development of gene editing tools, which enable the specific targeting and correction of mutations, hold the promise of allowing us to correct those mutations that cause genetic diseases. However, the technology has been around for a while nowtwo researchers were critical to its development in 2020and there have been only a few cases where gene editing has been used to target diseases.

One of the reasons for that is the challenge of targeting specific cells in a living organism. Many genetic diseases affect only a specific cell type, such as red blood cells in sickle cell anemia, or specific tissue. Ideally, to limit potential side effects, we'd like to ensure that enough of the editing takes place in the affected tissue to have an impact, while minimizing editing elsewhere to limit side effects. But our ability to do so has been limited. Plus, a lot of the cells affected by genetic diseases are mature and have stopped dividing. So, we either need to repeat the gene editing treatments indefinitely or find a way to target the stem cell population that produces the mature cells.

On Thursday, a US-based research team said that they've done gene editing experiments that targeted a high-profile genetic disease: cystic fibrosis. Their technique largely targets the tissue most affected by the disease (the lung), and occurs in the stem cell populations that produce mature lung cells, ensuring that the effect is stable.

The foundation of the new work is the technology that gets the mRNAs of the COVID-19 mRNA vaccines inside cells. The nucleic acids of an mRNA are large molecules with a lot of charged pieces, which makes it difficult for them to cross a membrane to get inside of a cell. To overcome that problem, the researchers package the mRNA inside a bubble of lipids, which can then fuse with cell membranes, dumping the mRNA inside the cell.

This process, as the researchers note, has two very large advantages: We know it works, and we know it's safe. "More than a billion doses of lipid nanoparticlemRNA COVID-19 vaccines have been administered intramuscularly worldwide," they write, "demonstrating high safety and efficacy sustained through repeatable dosing." (As an aside, it's interesting to contrast the research community's view of the mRNA vaccines to the conspiracies that circulate widely among the public.)

There's one big factor that doesn't matter for vaccine delivery but does matter for gene editing: They're not especially fussy about what cells they target for delivery. So, if you want to target something like blood stem cells, then you need to alter the lipid particles in some way to get them to preferentially target the cells of your choice.

There are a lot of ideas on how to do this, but the team behind this new work found a relatively simple one: changing the amount of positively charged lipids on the particle. In 2020, they published a paper in which they describe the development of selective organ targeting (SORT) lipid nanoparticles. By default, many of the lipid particles end up in the liver. But, as the fraction of positively charged lipids increases, the targeting shifts to the spleen and then to the lung.

So, presumably, because they know they can target the lung, they decide to use SORT particles to send a gene editing system specific to cystic fibrosis, which primarily affects that tissue, and is caused by mutations in a single gene. While it's relatively easy to get things into the lung, it's tough to get them to lung cells, given all the mucus, cilia, and immune cells that are meant to take care of foreign items in the lung.

Read more:
IV infusion enables editing of the cystic fibrosis gene in lung stem cells - Ars Technica

- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders

- ThermoStem is an off-the-shelf platform, well-protected by a comprehensive portfolio of issued patents that cover both the U.S. and international markets

- Potential license partner is a leading commercial stage regenerative medicine company

MELVILLE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative, BRTX or the Company) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today reported that it has had substantive discussions with an undisclosed commercial stage regenerative medicine company with regard to a license of BioRestoratives allogeneic, off-the-shelf ThermoStem metabolic intellectual property.

Previously published peer-reviewed preclinical data from a study conducted in collaboration with the University of Utah School of Medicine demonstrated a clonogenic population of metabolically active brown adipose tissue (BAT) stem cells residing in adult humans that: (i) can be expanded in vitro; (ii) exhibit multilineage differentiation potential (osteogenetic, chondrogenic and adipogenic); and (iii), functionally differentiate into metabolically active brown adipocytes. In addition, the preclinical results confirmed that multipotent brown adipose derived stem cells (BADSCs) induced to differentiate into brown adipocytes exhibit the mature functional properties of these cells, including increased mitochondrial activity, an important functional characteristic of BAT.

BADSCs with brown adipogenic potential would represent an exciting new modality for the treatment of obesity and related metabolic disorders. To explore this possibility, BioRestorative developed a 3D Porous Extracellular Matrix-Derived Scaffold for effective cell delivery. Data obtained in high-fat fed NOD-SCID mice transplanted with differentiated BADSCs supported by the 3D scaffold showed significant reductions in weight, triglyceride and blood glucose levels compared to saline-only injected controls.

No assurances can be given that a license agreement will be entered into whether on commercially reasonable terms or otherwise. The Company does not intend to make any further announcements with regard to the license unless and until an agreement is entered into.

It has been captivating to watch the scale, scope and speed with which potential license partners have begun to show interest in our proprietary off-the-shelf ThermoStem platform, said Lance Alstodt, BioRestoratives Chief Executive Officer. We are particularly pleased that our pioneering animal studies, which demonstrated that BADSCs show promise in correcting the weight gain and hyperglycemia associated with high fat feeding, and that our 3D scaffolds, which are capable of retaining viable transplanted cells for at least five weeks post-implantation, have attracted the caliber of commercial stage regenerative medicine company with which we are now engaged in substantive licensing discussions.

About BioRestorative Therapies, Inc.

BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we have also recently begun offering BioCosmeceutical products:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate,BRTX-100,is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. TheBRTX-100production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure,BRTX-100is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial usingBRTX-100to treat chronic lower back pain arising from degenerative disc disease.

Metabolic Program (ThermoStem): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (BADSC) to generate brown adipose tissue (BAT), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.BADSC secreted exosomes may also impact weight loss.

BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via Investigational New Drug (IND)-enabling studies, with the aim of pioneering U.S. Food and Drug Administration (FDA) approvals in the emerging BioCosmeceuticals space.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT: Email:ir@biorestorative.com

See the rest here:
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem Metabolic ... - GlobeNewswire

The University of Texas Health Science Center at San Antonio School of Dentistry is preparing to launch its Center for Regenerative Sciences, a new research initiative that aims to position the university at the forefront of regenerative dentistry and medicine.

The center will provide new avenues for interdisciplinary collaborations to accelerate the translation of preclinical discoveries into therapeutic benefit for patients suffering from dental, oral and craniofacial diseases, said Yong-Hee Chun, DDS, PhD, MS, associate professor of periodontics.

Chuns research focuses on understanding the molecules essential for tooth development and mineralization. When teeth and their support structures are malformed, such as with molar-incisor hypomineralization, or are damaged by diseases like periodontal disease, new treatments are needed. These treatments aim to regenerate the affected tissues and restore normal function, she said.

Anibal Diogenes, DDS, PhD, professor and chair of the Department of Endodontics, also highlighted the centers potential.

We have the capability to advance the field rapidly due to our ability to translate biological advancements into clinical applications faster than many other medical fields, he said. This center represents a huge opportunity to bootstrap the field, diversify our research and enhance collaboration among our scientists.

The Center for Regenerative Sciences will focus on several key areas, including the development of advanced tissue regeneration strategies, 3D printing of tissues and acellular scaffolds, the encapsulation of growth factors, morphogens and chemotactic molecules for targeted drug delivery.

Our goal is to create an environment within the body where biological cues guide cells to achieve their full potential, Diogenes said. By integrating basic sciences with clinical applications, we can bridge gaps and push the field of regenerative dentistry forward.

The center intends to accomplish this by leveraging and expanding the schools existing strengths in regenerative endodontics, dental and craniofacial development and the advancement of reliable sources of potent stem cells.

Diogenes research, for example, includes work on stem cell-based root canal therapies for children.

When a childs dental pulp is damaged or infected, we can activate their own stem cells to reestablish the pulp and allow the tooth to continue developing, which is crucial for their overall growth and development, he noted. This has significant implications not only for a childs dental health but also for their nutrition, speech development and psychosocial well-being.

Brij B. Singh, PhD, associate dean of research at the school, spoke to the broader impact of the new center.

This initiative will not only enhance our research capabilities but will attract top talent from various fields, creating a collaborative environment that can lead to breakthroughs in both dental and medical sciences, he said. The vision is to become a global leader in regenerative sciences, ultimately improving patient care outcomes everywhere.

The body has amazing regenerative capacity and the oral cavity is very special, Diogenes said. Its very rich in stem cells that are extremely potent with a high regenerative capacity. They are also unique because oral stem cells come from an origin where they can even become neurons. This means they have the potential to be used as therapies in many neurodegenerative diseases such as Alzheimers or Parkinsons therapies and for spinal cord injuries. There is so much potential there that extends far beyond the oral and craniofacial structures.

The Center for Regenerative Sciences will be formally launched by the school later this fall. It will be one of three centers of dental research, joining the Center for Global and Community Oral Health and the Center for Pain Therapeutics and Addiction Research. Recruitment for the centers director is currently underway.

For more information, visit the School of Dentistrys website.

Read more here:
School of Dentistry to launch new Center for Regenerative Sciences - UT Health San Antonio

THURSDAY, June 13, 2024 (HealthDay News) -- A telephone-delivered positive psychology intervention (Positive Affect for the Transplantation of Hematopoietic stem cells intervention [PATH]) is beneficial for allogeneic hematopoietic stem cell transplantation (HSCT) survivors, according to a study published online June 11 in the Journal of the National Comprehensive Cancer Network.

Hermioni L. Amonoo, M.D., M.P.H., from the Dana-Farber Cancer Institute in Boston, and colleagues randomly assigned HSCT survivors who were 100 days post-HSCT for hematologic malignancy to either PATH or usual care. PATH entailed nine weekly phone sessions on gratitude, personal strengths, and meaning and was delivered by a behavioral health expert.

Seventy-two of 105 eligible patients were enrolled. The researchers found that 91 percent of those randomly assigned to PATH completed all sessions and reported that the positive psychology exercises were easy to complete and subjectively useful. PATH participants reported greater improvements in gratitude, anxiety, and physical function compared with usual care at nine weeks and in gratitude, positive affect, life satisfaction, optimism, anxiety, depression, posttraumatic stress disorder, quality of life, physical functioning, and fatigue at 18 weeks.

"Cancer care providers should consider the potential benefits of psychosocial resources and interventions like PATH that focus on enriching positive emotions to bolster their patients' well-being," Amonoo said in a statement. "Encouraging patients to engage in simple, structured, and systematic exercises aimed at fostering positive thoughts and emotions, such as gratitude, has the potential to enhance well-being as well."

One author disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

See more here:
Positive Psychology Intervention Aids Allogeneic Stem Cell Transplant Survivors - HealthDay

Tran C, Damaser MS. Stem cells as drug delivery methods: application of stem cell secretome for regeneration. Adv Drug Deliv Rev. 2015;82:111.

Article PubMed Google Scholar

Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:419.

Article CAS PubMed Google Scholar

Han J, Hwang HS, Na K. TRAIL-secreting human mesenchymal stem cells engineered by a non-viral vector and photochemical internalization for pancreatic cancer gene therapy. Biomaterials. 2018;182:25968.

Article CAS PubMed Google Scholar

Zhang C-L, Huang T, Wu B-L, He W-X, Liu D. Stem cells in cancer therapy: opportunities and challenges. Oncotarget. 2017;8:75756.

Article PubMed PubMed Central Google Scholar

Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:273949.

Article CAS PubMed Google Scholar

Sagar J, Chaib B, Sales K, Winslet M, Seifalian A. Role of stem cells in cancer therapy and cancer stem cells: a review. Cancer Cell Int. 2007;7:111.

Article Google Scholar

Alvites R, Branquinho M, Sousa AC, Lopes B, Sousa P, Maurcio AC. Mesenchymal stem/stromal cells and their paracrine activityimmunomodulation mechanisms and how to influence the therapeutic potential. Pharmaceutics. 2022;14:381.

Article CAS PubMed PubMed Central Google Scholar

Song N, Scholtemeijer M, Shah K. Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharm Sci. 2020;41:65364.

Article CAS PubMed Google Scholar

Zhou Y, Yamamoto Y, Xiao Z, Ochiya T. The immunomodulatory functions of mesenchymal stromal/stem cells mediated via paracrine activity. J Clin Med. 2019;8:1025.

Article CAS PubMed PubMed Central Google Scholar

Park N, Kim KS, Na K. Stem cell-derived paracrine factors by modulated reactive oxygen species to enhance cancer immunotherapy. J Control Release. 2023;363:67081.

Article CAS PubMed Google Scholar

Xiao M, Tang Q, Zeng S, Yang Q, Yang X, Tong X, et al. Emerging biomaterials for tumor immunotherapy. Biomater Res. 2023;27:47.

Article CAS PubMed PubMed Central Google Scholar

Liesveld JL, Sharma N, Aljitawi OS. Stem cell homing: from physiology to therapeutics. Stem Cells. 2020;38:124153.

Article PubMed Google Scholar

Karp JM, Teo GSL. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4:20616.

Article CAS PubMed Google Scholar

Quesenberry PJ, Becker PS. Stem cell homing: rolling, crawling, and nesting. Proc Natl Acad Sci USA 1998;95:151557.

Article CAS PubMed PubMed Central Google Scholar

Hocking AM. The role of chemokines in mesenchymal stem cell homing to wounds. Adv Wound Care. 2015;4:62330.

Article Google Scholar

Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrdder H, Jensen T, et al. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene. 2004;23:50958.

Article CAS PubMed Google Scholar

Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, et al. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells. 2006;24:1095103.

Article PubMed Google Scholar

Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anticancer therapy. FASEB J. 2007;21:377785.

Article CAS PubMed Google Scholar

Finlan L, Hupp T. Epidermal stem cells and cancer stem cells: insights into cancer and potential therapeutic strategies. Eur J Cancer. 2006;42:128392.

Article CAS PubMed Google Scholar

Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev. 2004;14:437.

Article CAS PubMed Google Scholar

Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol/Hematol. 2004;51:128.

Article PubMed Google Scholar

de Almagro MC, Vucic D. Necroptosis: pathway diversity and characteristics. Semin Cell Dev Biol. 2015;39:5662.

Article PubMed Google Scholar

Newton K, Manning G. Necroptosis and inflammation. Annu Rev Biochem. 2016;85:74363.

Article CAS PubMed Google Scholar

Jorgensen I, Rayamajhi M, Miao EA. Programmed cell death as a defence against infection. Nat Rev Immunol. 2017;17:15164.

Article CAS PubMed PubMed Central Google Scholar

Ros U, Pea-Blanco A, Hnggi K, Kunzendorf U, Krautwald S, Wong WW-L, et al. Necroptosis execution is mediated by plasma membrane nanopores independent of calcium. Cell Rep. 2017;19:17587.

Article CAS PubMed PubMed Central Google Scholar

Choi ME, Price DR, Ryter SW, Choi AM. Necroptosis: a crucial pathogenic mediator of human disease. JCI insight. 2019;4:15.

Article Google Scholar

Berghe TV, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 2014;15:13547.

Article Google Scholar

Zhou H, Liu L, Ma X, Wang J, Yang J, Zhou X, et al. RIP1/RIP3/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage. Mol Cell Biochem. 2021;476:123343.

Article CAS PubMed Google Scholar

Liu Y, Liu T, Lei T, Zhang D, Du S, Girani L, et al. RIP1/RIP3-regulated necroptosis as a target for multifaceted disease therapy. Int J Mol Med. 2019;44:77186.

PubMed PubMed Central Google Scholar

Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer. 2019;18:117.

Article CAS Google Scholar

Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148:21327.

Article CAS PubMed Google Scholar

Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, et al. Mixed lineage kinase domain-like is a key receptor interacting protein 3 downstream component of TNF-induced necrosis. Proc Natl Acad Sci USA. 2012;109:53227.

Article CAS PubMed PubMed Central Google Scholar

Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang J-G, Alvarez-Diaz S, et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity. 2013;39:44353.

Article CAS PubMed Google Scholar

Dondelinger Y, Declercq W, Montessuit S, Roelandt R, Goncalves A, Bruggeman I, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 2014;7:97181.

Article CAS PubMed Google Scholar

Rodriguez D, Weinlich R, Brown S, Guy C, Fitzgerald P, Dillon C, et al. Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis. Cell Death Differ. 2016;23:7688.

Article CAS PubMed Google Scholar

Wang K-j WangK-y, Zhang H-z MengX-y, Chen J-f WangP, et al. Up-regulation of RIP3 alleviates prostate cancer progression by activation of RIP3/MLKL signaling pathway and induction of necroptosis. Front Oncol. 2020;10:1720.

Article PubMed PubMed Central Google Scholar

Silke J, Rickard JA, Gerlic M. The diverse role of RIP kinases in necroptosis and inflammation. Nat Immunol. 2015;16:68997.

Article CAS PubMed Google Scholar

Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013;38:20923.

Article CAS PubMed Google Scholar

Murao A, Aziz M, Wang H, Brenner M, Wang P. Release mechanisms of major DAMPs. Apoptosis. 2021;26:15262.

Article CAS PubMed PubMed Central Google Scholar

Vandenabeele P, Declercq W, Van Herreweghe F, Vanden Berghe T. The role of the kinases RIP1 and RIP3 in TNF-induced necrosis. Sci Signal. 2010;3:re4re4.

Article PubMed Google Scholar

Schmidt SV, Seibert S, Walch-Rckheim B, Vicinus B, Kamionka E-M, Pahne-Zeppenfeld J, et al. RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1 release, and efficient paracrine dendritic cell activation. Oncotarget. 2015;6:8635.

Article PubMed PubMed Central Google Scholar

Chen D, Yu J, Zhang L. Necroptosis: an alternative cell death program defending against cancer. Biochim Biophys Acta-Rev Cancer. 2016;1865:22836.

Article CAS Google Scholar

Wang R, Li H, Wu J, Cai Z-Y, Li B, Ni H, et al. Gut stem cell necroptosis by genome instability triggers bowel inflammation. Nature. 2020;580:38690.

Article CAS PubMed Google Scholar

Hu X-M, Zhang Q, Zhou R-X, Wu Y-L, Li Z-X, Zhang D-Y, et al. Programmed cell death in stem cell-based therapy: Mechanisms and clinical applications. World J Stem Cells. 2021;13:386.

Article PubMed PubMed Central Google Scholar

Hamann A, Nguyen A, Pannier AK. Nucleic acid delivery to mesenchymal stem cells: a review of nonviral methods and applications. J Biol Eng. 2019;13:116.

Article Google Scholar

Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20:136679.

Article CAS PubMed PubMed Central Google Scholar

Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017;43:60411.

Article CAS PubMed Google Scholar

Tan AC, Ashley DM, Lpez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA: Cancer J Clin. 2020;70:299312.

PubMed Google Scholar

Shergalis A, Bankhead A, Luesakul U, Muangsin N, Neamati N. Current challenges and opportunities in treating glioblastoma. Pharm Rev. 2018;70:41245.

Article CAS PubMed PubMed Central Google Scholar

Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168.

Article CAS PubMed PubMed Central Google Scholar

See the article here:
Human adipose-derived stem cells genetically programmed to induce necroptosis for cancer immunotherapy | Cancer ... - Nature.com